ARCHIVES

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

Oral Capecitabine Equal To 5FU-Leucovorin In Adjuvant Stage III Colon Cancer Treatment

June 25, 2004

In Brief: Glantz, Waxman, Wigand honored For Work Opposing tobacco; CTRC Names Executives

February 16, 1996

Oncotype DX Cancer Test Can Predict Recurrence

November 25, 2011

Foundations: Biomedical Foundation Formed to Support NIH

September 27, 1996

Charles Moertel, Mayo Clinic Investigator, Advocate Of Rigorous Trials, Dead At 66

July 8, 1994

NCI Advisory Group Meetings for September

August 29, 1975